Figure 1.

Viability of patient derived melanoma samples analyzed ex vivo for response to Vemurafenib. Lymph node metastases from 38 patients were disaggregated and cells plated and exposed to 2 μM Vemurafenib for 5 days as described in “Materials and Methods”. Viability was assessed using CellTiter-Glo® Luminescent Cell viability assay and results presented as percentage viable cells compared to untreated controls and correlated to BRAF mutation status (P < 0.0001, Student’s two-tailed t-test). 50% reduction in viability was chosen as cutoff for response/non-response. Gray bars; BRAF mutated, black bars; NRAS mutated, white bars; Double wild-type.